Gout therapeutics market projected to reach $5.6B by 2030 at 11.8% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Gout Therapeutics Market Between 2026 And 2030?

The gout therapeutics market size has shown substantial growth in recent years. It is projected to expand from $3.22 billion in 2025 to $3.59 billion in 2026, achieving an 11.6% compound annual growth rate (CAGR). The growth witnessed in the historic period can be attributed to dietary lifestyle changes, NSAID availability, increased arthritis diagnosis, hospital rheumatology services, and pain management drug development.

The gout therapeutics market is anticipated to experience substantial growth over the next few years. It is projected to expand to $5.6 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.8%. This expansion during the forecast period can be attributed to factors such as an aging population, the increasing burden of chronic diseases, advancements in preventive arthritis care, improved tools for patient compliance, and the implementation of personalized treatment approaches. Significant trends expected in the forecast period include the rising prevalence of arthritis related to lifestyle, the greater use of uric acid lowering therapies, the broadening of chronic gout management, increased awareness for early diagnosis, and enhanced long-term disease monitoring.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

What Key Factors Are Affecting The Gout Therapeutics Market Demand?

The increasing incidence of gout is anticipated to drive the expansion of the gout therapeutics market in the future. Gout is an inflammatory arthritis condition characterized by pain and swelling in the joints. This growing prevalence of gout mainly stems from obesity and metabolic syndrome, conditions that elevate uric acid levels in the blood, consequently forming urate crystals within the joints. Gout treatments are instrumental in decreasing both the incidence and intensity of gout by reducing uric acid concentrations, controlling inflammation, and averting acute attacks. For example, in June 2025, a publication cited by PubMed Central, a U.S.-based platform for biomedical and life sciences journals, reported that age-standardized gout incidence and prevalence rates are predicted to climb further by 2050, highlighting the expanding global burden of the disease. Additionally, in June 2024, data from The National Library of Medicine (NLM), a US-based largest biomedical library, indicated that in 2023, the USA saw 7.9 million cases of comorbid gout and chronic kidney disease (CKD), with projections suggesting a 29% increase to 9.6 million by 2035 under the baseline scenario. Consequently, the escalating incidence of gout is fueling the expansion of the gout therapeutics market.

What Segment Categories Shape The Gout Therapeutics Market Segment Landscape?

The gout therapeutics market covered in this report is segmented –

1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics

2) By Treatment: Xanthine Oxidase Inhibitor, Uricosuria Medication

3) By Disease Condition: Acute, Chronic

4) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, Selective COX-2 Inhibitors

2) By Corticosteroid: Oral Corticosteroids, Injectable Corticosteroids

3) By Diuretics: Thiazide Diuretics, Loop Diuretics

What Trends Are Influencing Changes In The Gout Therapeutics Market?

Leading companies in the gout therapeutics market are developing innovative products, such as urate transporters, which manage the reabsorption of uric acid from the urine back into the blood. A urate transporter is a protein that aids in moving uric acid (urate) across cell membranes in the kidneys or intestines, helping to regulate blood uric acid levels. For instance, in July 2025, Eisai Co. Ltd., a Japan-based pharmaceutical company, launched URECE (dotinurad), a selective urate transporter 1 (URAT1) inhibitor, which is being commercialized under Eisai’s global specialty care portfolio. URECE is used to treat hyperuricemia associated with gout, working to lower serum uric acid levels by increasing its excretion via the kidneys. Additionally, it offers a favorable safety profile with minimal off-target effects and efficacy in patients with mild-to-moderate renal impairment, making it suitable for a broad range of gout patients.

Who Are The Companies Operating Across The Gout Therapeutics Market Value Chain?

Major companies operating in the gout therapeutics market are Takeda Pharmaceutical Company Ltd, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, Teijin Pharma Ltd, Zydus Group, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Limited, Ironwood Pharmaceuticals Inc, Pharvaris NV, Selecta Biosciences Inc, Dyve Biosciences Inc, Arthrosi Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC

Get The Full Gout Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

Which Geographic Region Dominates The Gout Therapeutics Market?

North America was the largest region in the gout therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gout Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Gout Therapeutics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Gouty Arthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report

Ursolic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/ursolic-acid-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795